Replimune Group (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic(TM) platform, has closed an underwritten public offering of 5,625,000 shares of its common stock, including 937,500 additional shares per the full exercise of the over-allotment option granted to the underwriters. According to the update, each of the shares was sold at the public offering price of $40.00. In addition, in lieu of common stock to certain investors, Replimune also closed a sale of 1,562,500 shares of its common stock at the purchase price of $39.9999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant. Replimune Group secured approximately $287.5 million in gross proceeds in the offering, with all securities offered by Replimune.
To view the full press release, visit https://ibn.fm/E8JPB
About Replimune Group Inc.
Replimune Group, headquartered in Woburn, Massachusetts, was founded in 2015 to develop the next generation of oncolytic immuno-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune’s Immulytic(TM) platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. For more information, please visit www.Replimune.com.
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
InvestorWire is part of the InvestorBrandNetwork.